Immunogenicity of Salmonella typhi Ty21a vaccine for young children

Infect Immun. 1991 Nov;59(11):4291-3. doi: 10.1128/iai.59.11.4291-4293.1991.

Abstract

An attenuated Salmonella typhi Ty21a vaccine was administered to 18 infants and toddlers (less than or equal to 24 months old) to determine its safety and immunogenicity. The vaccination (10(9) CFU per dose, three doses) was well tolerated. However, after the vaccination there was no evidence of a humoral or cellular immune response to S. typhi. The vaccine used was known to be immunogenic for older children and adults. The results support the view that the immunogenicity of Ty21a is age dependent.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Oral
  • Age Factors
  • Antibodies, Bacterial / biosynthesis*
  • Antigens, Bacterial / immunology
  • Bacterial Vaccines / immunology*
  • Bacterial Vaccines / standards
  • Humans
  • Immunization
  • In Vitro Techniques
  • Infant
  • Lymphocyte Activation*
  • Salmonella typhi / immunology*
  • Vaccines, Attenuated / immunology
  • Vaccines, Attenuated / standards

Substances

  • Antibodies, Bacterial
  • Antigens, Bacterial
  • Bacterial Vaccines
  • Vaccines, Attenuated